These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 34887861)

  • 1. S100A2 Is a Prognostic Biomarker Involved in Immune Infiltration and Predict Immunotherapy Response in Pancreatic Cancer.
    Chen Y; Wang C; Song J; Xu R; Ruze R; Zhao Y
    Front Immunol; 2021; 12():758004. PubMed ID: 34887861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction of immune-related signature and identification of S100A14 determining immune-suppressive microenvironment in pancreatic cancer.
    Wang C; Chen Y; Xinpeng Y; Xu R; Song J; Ruze R; Xu Q; Zhao Y
    BMC Cancer; 2022 Aug; 22(1):879. PubMed ID: 35953822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of tumour immune microenvironment-related alternative splicing events for the prognostication of pancreatic adenocarcinoma.
    Chen B; Deng T; Deng L; Yu H; He B; Chen K; Zheng C; Wang D; Wang Y; Chen G
    BMC Cancer; 2021 Nov; 21(1):1211. PubMed ID: 34772375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma.
    Wang L; Zhang S; Li H; Xu Y; Wu Q; Shen J; Li T; Xu Y
    BMC Cancer; 2021 Jul; 21(1):876. PubMed ID: 34332578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
    Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
    Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High expression of S100A2 predicts poor prognosis in patients with endometrial carcinoma.
    Zhang Q; Xia T; Qi C; Du J; Ye C
    BMC Cancer; 2022 Jan; 22(1):77. PubMed ID: 35042454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Negative prognostic impact of PD-L1 expression in tumor cells of undifferentiated (anaplastic) carcinoma with osteoclast-like giant cells of the pancreas: study of 13 cases comparing ductal pancreatic carcinoma and review of the literature.
    Hrudka J; Lawrie K; Waldauf P; Ciprová V; Moravcová J; Matěj R
    Virchows Arch; 2020 Nov; 477(5):687-696. PubMed ID: 32424767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel lactylation-related signature to predict prognosis for pancreatic adenocarcinoma.
    Peng T; Sun F; Yang JC; Cai MH; Huai MX; Pan JX; Zhang FY; Xu LM
    World J Gastroenterol; 2024 May; 30(19):2575-2602. PubMed ID: 38817665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 correlated gene expression profiles and tumor infiltrating lymphocytes in pancreatic cancer.
    Li J; Yin L; Chen Y; An S; Xiong Y; Huang G; Liu J
    Int J Med Sci; 2021; 18(14):3150-3157. PubMed ID: 34400885
    [No Abstract]   [Full Text] [Related]  

  • 10. Identifying and Validating an Acidosis-Related Signature Associated with Prognosis and Tumor Immune Infiltration Characteristics in Pancreatic Carcinoma.
    Tang P; Qu W; Wu D; Chen S; Liu M; Chen W; Ai Q; Tang H; Zhou H
    J Immunol Res; 2021; 2021():3821055. PubMed ID: 34993253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unraveling pancreatic ductal adenocarcinoma immune prognostic signature through a naive B cell gene set.
    Zhang S; Ta N; Zhang S; Li S; Zhu X; Kong L; Gong X; Guo M; Liu Y
    Cancer Lett; 2024 Jul; 594():216981. PubMed ID: 38795761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction and validation of a novel immunological model to predict prognosis in pancreatic ductal adenocarcinoma.
    Liu J; He M
    Int Immunopharmacol; 2024 Jun; 134():112266. PubMed ID: 38761784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNFSF9 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Pancreatic Cancer.
    Wu J; Wang Y; Jiang Z
    J Gastrointest Cancer; 2021 Mar; 52(1):150-159. PubMed ID: 32077004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
    Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
    J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a novel 10 immune-related genes signature as a prognostic biomarker panel for gastric cancer.
    Chen T; Yang C; Dou R; Xiong B
    Cancer Med; 2021 Sep; 10(18):6546-6560. PubMed ID: 34382341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apolipoprotein E is a prognostic factor for pancreatic cancer and associates with immune infiltration.
    Wu B; Yang X; Chen F; Song Z; Ding X; Wang X
    Cytokine; 2024 Jul; 179():156628. PubMed ID: 38704962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Up-regulation of S100P predicts the poor long-term survival and construction of prognostic signature for survival and immunotherapy in patients with pancreatic cancer.
    Zou W; Li L; Wang Z; Jiang N; Wang F; Hu M; Liu R
    Bioengineered; 2021 Dec; 12(1):9006-9020. PubMed ID: 34654352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival.
    Danilova L; Ho WJ; Zhu Q; Vithayathil T; De Jesus-Acosta A; Azad NS; Laheru DA; Fertig EJ; Anders R; Jaffee EM; Yarchoan M
    Cancer Immunol Res; 2019 Jun; 7(6):886-895. PubMed ID: 31043417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.